Conformation-X Therapeutics


Conformation-X Therapeutics is an immune-oncology company developing biologic and orally available small-molecule therapeutics that target immune checkpoints and the tumor microenvironment. The company reports conducting ex vivo and in vivo preclinical proof-of-concept studies for lead programs and has completed a funding round to support pipeline advancement.

Industries

Biotechnology
Therapeutics
Biotechnology Research

Nr. of Employees

small (1-50)

Conformation-X Therapeutics

Canton, Massachusetts, United States, North America


Products

Preclinical program targeting HHLA2

A preclinical therapeutic program targeting the HHLA2 immune checkpoint with reported ex vivo and in vivo proof-of-concept data.

Preclinical program targeting IL18BP

A preclinical therapeutic program addressing IL18BP with reported ex vivo and in vivo proof-of-concept data.

IL18BP program

A lead asset of Conformation-X Therapeutics with successful ex vivo and in vivo proof-of-concept studies, part of their innovative immune-oncology pipeline.

HHLA2 program

A lead asset of Conformation-X Therapeutics with successful ex vivo and in vivo proof-of-concept studies, targeting immune checkpoints in cancer therapy.

Expertise Areas

  • Immune-oncology
  • Tumor microenvironment therapeutics
  • Small-molecule immune checkpoint inhibitors
  • Biologic therapeutic development
  • Show More (2)

Key Technologies

  • Biologic therapeutics
  • Oral small-molecule drug development
  • In vivo preclinical models
  • Ex vivo functional assays
  • Show More (2)

News & Updates

Announcement of an oversubscribed funding tranche of $3.65M, bringing total raised to over $13.5M, and disclosure of successful ex vivo and in vivo proof-of-concept studies for HHLA2 and IL18BP programs.

Closed an oversubscribed funding tranche of $3.65M, bringing total capital raised since inception to over $13.5M.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.